Trial Profile
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Surotomycin (Primary) ; Vancomycin
- Indications Clostridium difficile infections; Diarrhoea; Intestinal infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Cubist Pharmaceuticals; Merck & Co
- 03 Aug 2020 the molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile isolates from patients with C. difficile infection
- 06 Sep 2017 Results published in the Journal of Antimicrobial Chemotherapy.
- 02 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.